0914 ECP Attralus
BioCentury & Getty Images

Emerging Company Profile

Attralus debuts with $25M series A to tackle systemic amyloidosis

Attralus looks to obtain clinical POC for first pan-amyloid therapy

Attralus aims to treat multiple types of amyloidosis, starting with ATTR and AL amyloidosis. 

Sep 15, 2020 | 1:31 AM GMT

Attralus debuted

Read the full 485 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE